

What Clinicians Want to Know: Addressing Current Questions Related to the Management of Renal Cell Carcinoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The Phase III STELLAR-304 trial is currently evaluating the combination of zanzalintinib and nivolumab in which of the following settings?
  - a. Adjuvant therapy for clear cell renal cell carcinoma (RCC)
  - b. First-line therapy for advanced non-clear cell RCC
  - c. Second-line therapy after prior immunotherapy for advanced clear cell RCC
  - d. Heavily pretreated non-clear cell RCC in patients with no acceptable alternative options
2. The Phase II KEYNOTE-B61 trial evaluating first-line pembrolizumab and lenvatinib for patients with advanced non-clear cell RCC demonstrated partial responses or better in which of the following histologic subtypes of disease?
  - a. Papillary
  - b. Chromophobe
  - c. Translocation
  - d. Unclassified
  - e. All of the above
3. Which of the following any-grade adverse events is most commonly associated with belzutifan?
  - a. Diarrhea
  - b. Edema
  - c. Fatigue
  - d. Cough
4. What was the approximate reduction in the risk of disease progression or death with the addition of cabozantinib to nivolumab and ipilimumab as first-line therapy for patients with intermediate risk RCC in the Phase III COSMIC-313 trial?
  - a. 8%
  - b. 16%
  - c. 32%
  - d. 64%
5. Which of the following best describes progression-free survival (PFS) results with subcutaneous versus intravenous nivolumab for patients with previously treated advanced clear cell RCC in the Phase III CheckMate 67T trial?
  - a. PFS was inferior with subcutaneous nivolumab
  - b. PFS was similar with subcutaneous nivolumab
  - c. PFS was significantly improved with subcutaneous nivolumab